Sirtex Medical announced that the results of trials for its liver cancer treatment had been well accepted by the medical community.
Its shares were up 15% to $30.70 in early trade.
Shares in Sirtex Medical have been on a tear since the biotech announced last month an improved survival rates for liver cancer patients using its radioactive spheres treatment.
A study shows an additional 7.9 months to 20.5 months in the survival of liver cancer patients whose treatment included SIR-Spheres.
NOW WATCH: Briefing videos
Business Insider Emails & Alerts
Site highlights each day to your inbox.